Biblio

Author Title Type [ Year

]

Filters: Author is Taylor, Michael D [Clear All Filters]

2019

Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutiérrez-Fernández A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I, et al. Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma. Nature. 2019.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, et al. Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. Nat Rev Clin Oncol. 2019.

Zapotocky M, Beera K, Adamski J, Laperierre N, Guger S, Janzen L, Lassaletta A, Nobre LFigueiredo, Bartels U, Tabori U, et al. Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer. 2019.

Shuai S, Suzuki H, Diaz-Navarro A, Nadeu F, Kumar SA, Gutiérrez-Fernández A, Delgado J, Pinyol M, López-Otín C, Puente XS, et al. The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature. 2019.

2018

Forget A, Martignetti L, Puget S, Calzone L, Brabetz S, Picard D, Montagud A, Liva S, Sta A, Dingli F, et al. Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell. 2018;34(3):379-395.e7.

Pajtler KW, Wen J, Sill M, Lin T, Orisme W, Tang B, Hübner J-M, Ramaswamy V, Jia S, Dalton JD, et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol. 2018.

Kumar KSanthana, Neve A, Stucklin ASGuerreir, Kuzan-Fischer CM, Rushing EJ, Taylor MD, Tripolitsioti D, Behrmann L, Kirschenbaum D, Grotzer MA, et al. TGF-β Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma. Cell Rep. 2018;23(13):3798-3812.e8.

2016

A Morrissy S, Garzia L, Shih DJH, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FMG, Ramaswamy V, Lindsay PE, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016.

Pei Y, Liu K-W, Wang J, Garancher A, Tao R, Esparza LA, Maier DL, Udaka YT, Murad N, Morrissy S, et al. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. Cancer Cell. 2016;29(3):311-323.

Oh S, Flynn RA, Floor SN, Purzner J, Martin L, Do BT, Schubert S, Vaka D, Morrissy S, Li Y, et al. Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. Oncotarget. 2016.

Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell. 2016;164(5):1060-1072.

2015

Huang X, He Y, Dubuc AM, Hashizume R, Zhang W, Reimand J, Yang H, Wang TA, Stehbens SJ, Younger S, et al. EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nat Neurosci. 2015.

Mack SC, Hubert CG, Miller TE, Taylor MD, Rich JN. An epigenetic gateway to brain tumor cell identity. Nat Neurosci. 2015;19(1):10-19.

Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, Bryant M, Bebenek M, Wang X, Bertrand KC, et al. Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget. 2015.

Vuong B, Skowron P, Kiehl T-R, Kyan M, Garzia L, Sun C, Taylor MD, Yang VXD. Measuring the optical characteristics of medulloblastoma with optical coherence tomography. Biomed Opt Express. 2015;6(4):1487-501.

Ramaswamy V, Nör C, Taylor MD. p53 and Meduloblastoma. Cold Spring Harb Perspect Med. 2015.

Mack SC, Agnihotri S, Bertrand KC, Wang X, Shih DJ, Witt H, Hill N, Zayne K, Barszczyk M, Ramaswamy V, et al. Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res. 2015.

2014

Schneider C, Ramaswamy V, Kulkarni AV, Rutka JT, Remke M, Tabori U, Hawkins C, Bouffet E, Taylor MD. Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. J Neurosurg Pediatr. 2014:1-7.

Forget A, Bihannic L, Cigna SMaria, Lefevre C, Remke M, Barnat M, Dodier S, Shirvani H, Mercier A, Mensah A, et al. Shh Signaling Protects Atoh1 from Degradation Mediated by the E3 Ubiquitin Ligase Huwe1 in Neural Precursors. Dev Cell. 2014;29(6):649-661.

2013

Pambid MRose, Berns R, Adomat HH, Hu K, Triscott J, Maurer N, Zisman N, Ramaswamy V, Hawkins CE, Taylor MD, et al. Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. Pediatr Blood Cancer. 2013.

Triscott J, Lee C, Foster C, Manoranjan B, Pambid MRose, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, et al. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase PLK1 as a molecular target in high-risk children. Cancer Res. 2013.

Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, Gerß J, Schulz S, Hielscher T, Hasselblatt M, et al. Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst. 2013.

Pages